Roche and reMYND's DDD enter into a strategic alliance to develop first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease

Press release | Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting α-synuclein and tau toxicity.

reMYND and Amorfix announce agreement

Press release | Amorfix Life Sciences Ltd. (TSX:AMF) and reMYND nv today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in‐vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).

Ablynx and reMYND settle dispute amicably

Press release | Ablynx nv [Euronext Brussels: ABLX] and reMYND nv announced today that they have reached a settlement concerning a dispute relating to a collaboration agreement to discover and commercialize new Nanobodies® which Ablynx and reMYND entered into in 2003.

reMYND receives a grant of 0.9 million EUR from IWT

reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). Visit the IWT website

reMYND receives license renewal from Schering-Plough for RadarScreen

Press release | reMYND nv announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough (NYSE ticker: SGP) for the supply and use of RadarScreen, a novel yeast-based screening system that allows the rapid and cost-effective identification of genotoxic compounds in e